Tobacco Use Disorder Clinical Trial
Official title:
Phase IIA Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci)
Chemoprevention is the use of certain substances to keep cancer from forming, growing, or coming back. Curcumin is a compound found in plants that may prevent colon cancer from forming. This phase II trial is studying how well curcumin works in preventing colon cancer in smokers with aberrant crypt foci.
PRIMARY OBJECTIVES:
I. To determine mean percentage change from baseline in prostaglandin E2 (PGE2) within ACF
pre and post 30 days of curcumin administration at a specified dose.
SECONDARY OBJECTIVS:
I. To determine mean percentage change from baseline in 5-hydroxy-eicosatetraenoic acid
(5-HETE) within ACF pre and post 30 days of curcumin administration at a specified dose.
II. To determine mean percentage change from baseline in PGE2 and 5-HETE within comparison
normal mucosa pre and post 30 days of curcumin administration at a specified dose.
III. To quantify corresponding enzyme changes in the cyclooxygenases (COX-1, COX-2,) and
lipoxygenase (5-LOX) protein abundance. Semi-quantitative changes in these proteins will be
measured by western blotting and correlated with changes in prostaglandins and leukotrienes
respectively.
IV. Document changes in total ACF number. V. Determine proliferation by Ki-67 IHC in rectal
mucosa pre and post therapy and correlate with changes in ACF number and size.
VI. Determine curcumin concentration in rectal mucosa after 30 days therapy and correlate
with PGE2 and 5-HETE changes described above.
VII. Measure glutathione peroxidase (GPx) activity within the colon pre and post therapy as
an indirect marker of reduced oxidative stress within the colonic epithelium.
VIII. Ensure safety of all participants during course of study investigation. IX. Determine
the curcumin concentration in plasma before and after treatment.
OUTLINE: This is a multicenter, nonrandomized, uncontrolled study.
Patients receive 1 of 2 doses of oral curcumin once daily. Treatment continues for 30 days
in the absence of unacceptable toxicity or disease progression.
Blood and tissue biopsies are obtained by sigmoidoscopy or colonoscopy at baseline and at
day 30 for correlative biomarker studies. The change in prostaglandin E_2 (PGE_2) is
assessed by enzyme immunoassay, 5-hydroxy-eicosatetraenoic acid (5-HETE) by high-performance
liquid chromatography, cyclooxygenases (COX-1 and COX-2) and 5-lipoxygenase (5-LOX) by
western blotting, Ki-67 by immunohistochemistry, and glutathione peroxidase (GPx) by
spectrophotometric assay.
After completion of study therapy, patients are followed at 1 week.
PROJECTED ACCRUAL: A total of 48 patients will be accrued for this study.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02432066 -
Effects of GTS-21 on Smoking Behavior and Neurocognitive Functions
|
Phase 2 | |
Completed |
NCT03960138 -
Examining the Effects of Neural Stimulation on Inhibitory Control and Cigarette Smoking
|
N/A | |
Recruiting |
NCT05030272 -
Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings
|
N/A | |
Completed |
NCT04646668 -
Comparative Abuse Liability Among African American and White Smokers
|
N/A | |
Completed |
NCT02560324 -
Effect of Ramelteon on Smoking Abstinence
|
Phase 2 | |
Completed |
NCT02347605 -
Medicinal Nicotine for Preventing Cue Induced Craving
|
N/A | |
Completed |
NCT01442753 -
Family-Skills Training to Prevent Tobacco and Other Substance Use in Latino Youth
|
N/A | |
Completed |
NCT01625767 -
Tobacco Approach Avoidance Training for Adolescent Smokers-1
|
Phase 2 | |
Completed |
NCT01570595 -
Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV
|
Phase 1/Phase 2 | |
Terminated |
NCT01800500 -
Interest in Smokeless Tobacco Product as a Substitution for Cigarettes in Current Smokers
|
N/A | |
Completed |
NCT01428310 -
Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke
|
Phase 1 | |
Active, not recruiting |
NCT01539525 -
Screening to Augment Referral to Treatment- Project START
|
Phase 2 | |
Completed |
NCT01337817 -
A Pilot Study to Evaluate the Efficacy and Safety of Ariva® Silver Wintergreen in Healthy Smokers
|
Phase 1 | |
Completed |
NCT00967005 -
N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers
|
Phase 2 | |
Active, not recruiting |
NCT00751660 -
Screening Methods in Finding Lung Cancer Early in Current or Former Smokers
|
N/A | |
Completed |
NCT00790569 -
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
|
N/A | |
Completed |
NCT00664261 -
Clinical Effort Against Secondhand Smoke (CEASE) Program or Standard Care in Helping Parents Stop Smoking
|
N/A | |
Completed |
NCT00134927 -
A Survey on Consumer Use of Over-the-Counter (OTC) Nicotine Patches
|
N/A | |
Completed |
NCT00158145 -
Assessing the Variability Over Time of Tobacco Carcinogen Biomarkers in Smokers - 2
|
Phase 2 | |
Completed |
NCT01213524 -
Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia
|
Phase 2 |